PATH | VRL
Menu

Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study

This article, published in Clinical Infectious Diseases, reports the results of a study examining the safety and efficacy of a typhoid conjugate vaccine in people aged 6 months to 24 years conducted at eight trial sites in India. The results showed that a single dose of the vaccine was well tolerated and provided robust and long-lasting protection across age groups.

Author: Mohan VK, Varanasi V, Singh A, et al.

Published: 2015

» Visit web page (English)

(Located at academic.oup.com)

Citation: Mohan VK, Varanasi V, Singh A, et al. Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study. Clinical Infectious Diseases. 2015;61(3):393-402.

Resource types: Peer-reviewed journal

Diseases/vaccines: Typhoid

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Asia